Group One Trading’s Eidos Therapeutics, Inc. Common Stock EIDX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q1
Sell
-5,600
Closed -$737K 8293
2020
Q4
$737K Buy
5,600
+1,300
+30% +$115K ﹤0.01% 2921
2020
Q3
$217K Buy
4,300
+4,200
+4,200% +$189K ﹤0.01% 3587
2020
Q2
$5K Sell
100
-9,400
-99% -$437K ﹤0.01% 5396
2020
Q1
$465K Buy
9,500
+9,000
+1,800% +$459K ﹤0.01% 2101
2019
Q4
$29K Buy
+500
New +$24.8K ﹤0.01% 4241

Group One Trading's EIDX Position: Q2 2020 in Review

Group One Trading sold out of Eidos Therapeutics, Inc. Common Stock (EIDX) in Q2 2020, closing a stake of 2,035 shares — an estimated $94.6K sold.

Group One Trading first reported a position in EIDX in Q4 2019 and held it in 2 quarters. The position peaked at $100K in Q1 2020. 92 funds tracked by Wall St. Rank hold EIDX as of Q2 2020.

  • Group One Trading reported no remaining Eidos Therapeutics, Inc. Common Stock position as of Q2 2020 after selling out during the quarter.
  • Group One Trading sold 2,035 Eidos Therapeutics, Inc. Common Stock shares in Q2 2020, an estimated $94.6K.
  • Group One Trading first reported a position in Eidos Therapeutics, Inc. Common Stock in Q4 2019 and held it in 2 quarters.
  • Group One Trading's Eidos Therapeutics, Inc. Common Stock position peaked at $100K in Q1 2020.
  • 92 funds tracked by Wall St. Rank held Eidos Therapeutics, Inc. Common Stock as of Q2 2020.

Based on Group One Trading's 13F filing for Q2 2020, filed 13 Aug 2020.